Target intelligence / Profile preview

Tetratricopeptide repeat domain 5 (TTC5)

Target
TTC5
Molecular classification
Other (specifically: Tetratricopeptide repeat (TPR) domain–containing scaffold/adaptor protein), Transcription cofactor
01

Overview

Tetratricopeptide repeat domain 5 (TTC5) is a conserved protein containing multiple tetratricopeptide repeat (TPR) motifs, which are structural domains mediating protein–protein interactions and the assembly of multiprotein complexes[2][5]. TTC5 acts as a transcriptional cofactor and adaptor protein, regulating key cellular processes such as the DNA damage response, TP53/p53 stabilization and activation, heat-shock response, chromatin modification, autophagy, actin dynamics, and mRNA catabolism[3][4][5]. In stress conditions, TTC5 forms complexes with the histone acetyltransferase p300 (EP300) and coactivators like JMY to facilitate the activation of p53-dependent gene expression, promoting cell cycle arrest or apoptosis after DNA damage[3][4][5]. TTC5 is also required for survival and self-renewal of acute myeloid leukemia (AML) cells, acting partly through positive regulation of anti-apoptotic BCL2 expression and suppression of pro-apoptotic gene expression, in cooperation with p300/EP300[3]. TTC5 is broadly expressed, including in hematopoietic tissues; its dysfunction is associated with neurodevelopmental disorders and intellectual disability[4]. No approved drugs directly target TTC5, but its critical roles in apoptosis and cancer reveal potential therapeutic interest, particularly in hematological malignancies[3].

Other names
Tetratricopeptide repeat protein 5TPR repeat protein 5Protein StrapStrapStress-responsive activator of p300
02

Biological functions

Protein–protein interaction scaffoldDNA damage responseRegulation of TP53/p53 activityRegulation of autophagyRegulation of actin dynamicsRegulation of chromatin modificationRibosome binding and mRNA catabolismRegulation of apoptosisRegulation of heat-shock response
03

Disease associations

Cancer (notably acute myeloid leukemia)Neurodevelopmental disorder with cerebral atrophy and variable facial dysmorphismIntellectual disability (autosomal recessive non-syndromic)
04

Safety considerations

No direct human safety data, but given its role in apoptosis, stress response, and hematopoiesis, targeted inhibition could impact normal cell survival and stress response pathways

Beyond the preview

Go deeper on Tetratricopeptide repeat domain 5 (TTC5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tetratricopeptide repeat domain 5 (TTC5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call